文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

mRNA新冠疫苗对西班牙长期护理机构老年居民预防感染、住院和死亡的效果

Effectiveness of mRNA COVID-19 vaccines in preventing SARS-CoV-2 infections and COVID-19 hospitalisations and deaths in elderly long-term care facility residents, Spain, weeks 53 2020 to 13 2021.
PubMed 文献 · Euro Surveill · 2021-01-01

本研究采用筛查方法和基于人群的数据源,评估西班牙长期护理机构老年居民接种mRNA新冠疫苗对SARS-CoV-2感染、COVID-19住院和死亡的有效性。结果显示疫苗对感染(有症状和无症状)的有效性为71%(95%CI:56-82%),对住院为88%(95%CI:75-95%),对死亡为97%(95%CI:92-99%)。

要点

  • mRNA疫苗对长期护理机构老年居民SARS-CoV-2感染有效性71%(95%CI:56-82%)
  • 对COVID-19住院有效性88%(95%CI:75-95%)
  • 对COVID-19死亡有效性97%(95%CI:92-99%)

核心结论

  • mRNA新冠疫苗对西班牙长期护理机构老年居民具有较高的预防感染、住院和死亡效果。

研究设计与样本

  • 采用筛查方法和基于人群的数据源,评估西班牙长期护理机构老年居民mRNA新冠疫苗有效性。

主要发现

  • 疫苗对SARS-CoV-2感染(有症状和无症状)的有效性为71%(95%CI:56-82%)。
  • 疫苗对COVID-19住院的有效性为88%(95%CI:75-95%)。
  • 疫苗对COVID-19死亡的有效性为97%(95%CI:92-99%)。

临床怎么用

  • 支持在长期护理机构老年居民中优先接种mRNA新冠疫苗以降低感染、住院和死亡风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Residents in long-term care facilities (LTCF) experienced a large morbidity and mortality during the COVID-19 pandemic in Spain and were prioritised for early COVID-19 vaccination. We used the screening method and population-based data sources to obtain estimates of mRNA COVID-19 vaccine effectiveness for elderly LTCF residents. The estimates were 71% (95% CI: 56-82%), 88% (95% CI: 75-95%), and 97% (95% CI: 92-99%), against SARS-CoV-2 infections (symptomatic and asymptomatic), and COVID-19 hospitalisations and deaths, respectively.

来源:Euro Surveill,查看原文。版权归原作者所有。

引用

  1. Mazagatos C, Monge S, Olmedo C, et al. Effectiveness of mRNA COVID-19 vaccines in preventing SARS-CoV-2 infections and COVID-19 hospitalisations and deaths in elderly long-term care facility residents, Spain, weeks 53 2020 to 13 2021. Euro Surveill. 2021. PMID: 34142647. doi:10.2807/1560-7917.ES.2021.26.24.2100452

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。